INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS

by | Sep 22, 2023 | News & Media

October 11-15, 2023

Biolexis Therapeutics Scientific Team participates and present their IND stage small molecule CDK9 inhibitor program for Pancreatic Cancers indications at The “AACR-NCI-EORTC” International Conference on Molecular Targets and Cancer Therapeutics to be held on Oct 11-15, 2023 – Haynes Convention Center, Boston, Massachusetts

Abstracts

Abstract title: Development of BLX-3030, A Potent, Selective, Orally Available CDK9i shows promise in Pancreatic Ductal Adenocarcinoma (PDAC) Models

Poster number:LB_C13 | Session: Poster Session C     

Session location: Level 2, Exhibit Hall D        

Session date and time: Saturday, October 14 | 12:30 pm-4:00 pm

 SOCIETY OF NEUROSCIENCE ANNUAL MEETING TO BE HELD 

November 11-15, 2023 Biolexis Therapeutics Scientific Team participates and present their pre-clinical stage small molecule HDAC6 inhibitor program for ALS indication at the “SfN” (Society of Neuroscience) Annual Meeting to be held on Nov 11-15, 2023 – Walter E....

14th Annual World Cancer Congress

July 22-24, 2023 Biolexis Therapeutics CSO invited to Chair Cancer Immunology & Immunotherapy session and present MolecuLern technology at 14th Annual World Cancer Congress – WCC 11: Cancer Immunology & Immunotherapy on July 22-24, 2023, at Barcelona, Spain....